The European Medicines Agency welcomes Enrica Alteri, starting today as the new Head of Safety and Efficacy of Medicines in the Human Medicines Development and Evaluation Unit.
Dr Alteri, a medical doctor, brings a wealth of managerial experience with her. Her career to date has focused on the safety of medicines in the pharmaceutical industry, most recently as Head of Risk Management and Epidemiology at Merck-Serono in Geneva.
Her arrival coincides with the start of the application of the new pharmacovigilance legislation today, when the Sector begins to take on responsibilities in addition to its core business of overseeing the scientific evaluation of applications for marketing authorisation for human medicines.
Dr Alteri takes over from Xavier Luria, who held the position until March 2012 and Francesco Pignatti, the Agency’s Head of Oncology, who has also been Acting Head of Safety and Efficacy of Medicines since March. The Agency thanks Drs Luria and Pignatti for their work in the role.
As for all staff members, Dr Alteri is required to declare her interests in the pharmaceutical industry and to have divested herself of any shares in pharmaceutical companies before starting work at the Agency. The Agency uses the information in each staff member’s declaration of interests to determine his or her level of involvement in specific activities, such as the evaluation of a particular medicine. For Dr Alteri, all involvement in medicines from Merck-Serono and Stallergenes will be transferred to her back-up manager.
Dr Alteri’s declaration of interests and biography are available under Human Medicines Development and Evaluation.